Cipla has been on a wonderful run on the bourses for the past few days. It has been hitting a new high consistently for the past three consecutive days. Today’s new high stands at Rs.746.50.

The company yesterday announced that Stempeutics Research, a group company of Manipal

Education and Medical Group and a Joint Venture with Cipla Group, announced today that the United States Patent and Trademarks Office (USPTO) granted a US process patent for its novel stem-cell based drug Stempeucel®, which will initially be used for the treatment of CLI and is a breakthrough treatment option which directly addresses the root cause of the disease, unlike other drugs which typically treat the symptoms and not the disease itself.

This is the first company in the world to be granted a US process patent for a stem cell drug based on pooling technology.